Overview: Recent Advances in Angiotensin II Receptor Antagonists

References

• DZAU VJ, PRATT RE: Renin-angiotensin sys-tem: biology, physiology and pharmacol-ogy. In: The Heart and Cardiovascular Sys-tem. (1986) Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (Eds), Raven Press, New York, pp1631–1662.
   Google Scholar
• WONG PC, CHIU AT, PRICE WA JR, THOOLEN MJ, CARINI DJ, JOHNSON AL, TABER RI, TRVIMERMANS PB: Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-l-(2-chlorobenzyffimidazole-5-acetic acid, sodium salt (S-8307). J. PharmacoL Exp. Then (1988) 247:1–7.
   Google Scholar
• DUNCIA iv, CARINI DJ, CHIU AT, PIERCE ME, PRICE WA JR, SMITH RD, WELLS GJ, WONG PC, WEXLER RR, JOHNSON AL, TIMMERMANS PB: DuP-753, Losartan potassium, MK-954. Drugs of the Future (1992) 17:326–331.
   Google Scholar
• DUNCIA iv, CARINI DJ, Cmu AT, JOHNSON AL, PRICE WA JR, WONG PC, WEXLER RR, TIMMERMANS PB: The discovery of DuP 753, a potent, orally active nonpeptide angio-tensin II receptor antagonist. Med. Res. Rev. (1992) 12:149–191.
   PubMedGoogle Scholar
• SMITH RD, CHIU AT, WONG PC, HERBLIN WF, TTMMERMANS PB: Pharmacology of nonpep-tide angiotensin II receptor antagonists. Ann. Rev. PharmacoL ToxicoL (1992) 32:135–165.
   PubMed Web of Science ®Google Scholar
• TTMMERMANS PB, WONG PC, CHIU AT, HERB- LIN WF: Nonpeptide angiotensin II receptor antagonists. TIPS (1991) 12:55–62.
   PubMedGoogle Scholar
• CHRISTEN Y, WAEBER B, NUSSBERGER J, PORCHET M, BORE RM, LEE RI, MAGGON K, SHRUM L, TIMMERMANS PB, BRUNNER HR: Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to nor-mal male volunteers-Inhibition of the pres-sor response to exogenous angiotensin I and H. Circulation (1991) 83:1333–1342.
   PubMed Web of Science ®Google Scholar
• NELSON E, MERRILL D, SWEET C, BRADSTREET T, PANEBIANCE R, BYYOY T, HERMAN K, LASSITER B, LEVY G, LEWIS FG, MCHAHON R, REEVES D, RUFF A, SHEPHERD D, WEIDLER J, IRVIN J: Efficacy and safety of oral MK- 954, DuP 753 and angiotensin receptor antagonists in essential hypertension. Fifth European Meeting on Hypertension, Eur. Soc. of Hypertension (1992) Milan, Italy, 512.
   Google Scholar
• STEARNS RA, MILLER RR, DOSS GA, CHAKRA-VARTY PK, ROSEGAY R, GATTO GJ, LEE CS-H: The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey and human liver slices. Drug Metab. &Disp. (1992)20:281–287.
   PubMed Web of Science ®Google Scholar
• STEARNS RA, Doss GA, MILLER RR, LEE CS-H: Synthesis and identification of a novel te-trazole metabolite of the angiotensin II re-ceptor antagonist DuP 753. Drug Metab. & Disp. (1992) 19:1160–1162.
   Google Scholar
• DOUGLAS JD: Angiotensin receptor subtypes of the kidney cortex. Am. J. PhysioL (1987) 253:Fl-F7.
   Google Scholar
• REID LA: Actions of angiotensin II on the brain: mechanisms physiologic role. Am. J. Physiol. (1984) 246:F533–F543.
   Google Scholar
• BLANKLEY CJ, HODGES JC, KLUTCHKO SR, HIMMELSBACH RI, CHUCHOLOWSKI A, CON-NOLLY CJ, NEERGAARD SJ, VAN NIEUWENHZE MS, SEBASTIAN A, QUTN J: Synthesis and structure-activity relationships of a novel se-ries of nonpeptide angiotensin II receptor binding inhibitors specific for the AT2 sub-type. J. Med. Chem. (1991) 34:3248–3260.
   PubMed Web of Science ®Google Scholar
• HODGES JC, HAMBY JM, BLANKLEY CJ: An- giotensin II receptor binding inhibitors. Drugs of the Future (1992) 17:575–593.
   Google Scholar
• CHIU AT, HERBLIN WF, MCCALL DE, ARDECKY RI, CARINI DJ, DUNCIA JV, PEASE LJ, WONG PC, WEXLER RR, JOHNSON AL, TIMMERMANS PB: Identification of angiotensin II recep-tor subtypes. Biochem. Biophys. Res. Com-mun. (1989) 165:196–203.
   PubMed Web of Science ®Google Scholar
• DUDLEY DT, PANEK RL, MAJOR TC, LU GH, BRUNS RF, KLINKEFUS BA, HODGES JC, WEISHAAR RE: Subclasses of angiotensin II binding sites and their functional signifi-cance. Mol. Pharm. (1990) 38:370–377.
   PubMed Web of Science ®Google Scholar
• WHITEBREAD S, MELE M, KAMBER B, DE GASPARO M: Preliminary biochemical char- acterization of two angiotensin II receptor subtypes. Biochem. Biophys. Res. Commun. (1989) 163:284–291.
   PubMed Web of Science ®Google Scholar
• MURPHY TJ, ALEXANDER RW, GRIENDLING KK, RUNGE MS, BERSTEIN KE: Isolation of a cDNA encoding the vascular type-1 angio-tensin II receptor. Nature (1991) 351:233–236.
   PubMed Web of Science ®Google Scholar
• SASAKI K, YAMANO Y, BARDHAN S, IWAI N, MURRAY JJ, HASEGAWA M, MATSUDA Y, INAGAMI T: Cloning and expression of a com-plementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (1991) 351:230–233.
   PubMed Web of Science ®Google Scholar
• YAMANO Y, OHYAMA K, CHAKI S, GUO D, INAGAMI T: Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagene-sis. Biochem. Biophys. Res. Commun. (1992) 187:1426–1431.
   PubMedGoogle Scholar
• STRADER CD, SIGAL IS, DIXON RA: Struc-tural basis of beta-adrenergic receptor func-tion. FASEB J. (1989) 3:1825–1832.
   PubMed Web of Science ®Google Scholar
• STRADER CD AND DKON RA: Genetic analy-sis of the beta-adrenergic receptor. Adv. Exp. Med. Biol. (1991) 287:209–220.
   PubMedGoogle Scholar
• STRADER CD, SIGAL IS, CANDELORE MR, RANDS E, HILL WS, DDCON RA: Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J. Biol. Chem. (1988) 263:10267–10271.
   PubMed Web of Science ®Google Scholar
• STRADER CD, CANDELORE MR, HILL WS, SIGAL IS, DIXON RA: Identification of two serine residues involved in agonist activation of the ^-adrenergic receptor. I. Biol. Chem. (1989) 264:13572–13578.
   Google Scholar
• ELTON TS, STEPHAN CC, TAYLOR GR, KIMBALL MG, MARTIN MM, DURAND JN, OPARIL S: Isolation of two distinct type I angiotensin II receptor genes. Biochem. Biophys. Res. Com-mun. (1992) 184:1067–1073.
   PubMed Web of Science ®Google Scholar
• SANDBERG K, HONG J, CLARK AJ, SHAPIRA H, CATT KJ: Cloning and expression of a no-vel angiotensin II receptor subtype. J. Biol. Chem. (1992) 267:9455–9458.
   PubMed Web of Science ®Google Scholar
• KAKAR SS, SELLERS JC, DEVOR DC, MUSGROVE LC, NEILL ID: Angiotensin II type-1 receptor subtype cDNAs: Differential tissue expres-sion and hormonal regulation. Biochem. Bio-phys. Res. Commun. (1992) 183:1090–1096.
   PubMed Web of Science ®Google Scholar
• SASAMURA H, HEIN L, KRIEGER JE, PRATT RE, KOBILKA BK, DZAU VJ: Cloning, char-acterization, expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem. Biophys. Res. Commun. (1992) 185:252–259.
   Google Scholar
• YOSHIDA H, KAKUCHI J, GUO D-F, FURUTA H, IWAI N, VAN DER MEER-DE JONG R, INAGAMI T, ICHIKAWA I: Analysis of the evolution of angiotensin II type I recep-tor gene in mammals (mouse, rat, bovine and human). Biochem. Biophys. Res. Corn-mun. (1992) 186:1042–1049.
   PubMedGoogle Scholar
• TAKAYANAGI R, OHNAKA K, SAKAI Y, NAKAO R, YANASE T, HAJI M, INAGAMI T, FURUTA H, GUO D-F, NAKAMUTA M, NAWATA H: Molec-ular cloning, sequence analysis and expres-sion of a cDNA encoding human type-1 an-giotensin II receptor. Biochem. Biophys. Res. Commun. (1992) 183:910–916.
   PubMedGoogle Scholar
• FURUTA H, GUO D-F, INAGAMI T: Molecu-lar cloning and sequencing of the gene en-coding human angiotensin II type 1 recep-tor. Biochem. Biophys. Res. Commun. (1992) 183:8–13.
   PubMedGoogle Scholar
• BERGSMA DJ, ELLIS C, KUMAR C, NUTHULA-GANTI P, KERSTEN H, ELSHOURBAGY N, GRIFFTN E, STADEL JM, AIYAR N: Cloning and characterization of a human angiotensin Ii type 1 receptor. Biochem. Biophys. Res. Commun. (1992) 183:989–995.
   PubMed Web of Science ®Google Scholar
• CURNOW KM, PASCOE L, WHITE PC: Genetic analysis of the human type-1 angiotensin II receptor. Mol. Endo. (1992) 6:1113–1118.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI K AND SAAVEDRA JM: Differential development of angiotensin II receptor sub-types in the rat brain. Endocrinology (1991) 128:630–632.
   PubMedGoogle Scholar
• GRADY EF, SECHI LA, GRIFFIN CA, SCHAMB-ELAN M, KALINYAK JE: Expression of AT2 re-ceptors in the developing rat fetus. J. Clin. Invest. (1991) 88:921–933.
   PubMed Web of Science ®Google Scholar
• MILLAN MA, CARVALLO P, IZUMI S-I, ZEMEL S, CATT KJ, AGUILERA G: Novel sites of ex-pression of functional angiotensin II recep-tors in the late gestation fetus. Science (1989) 244:1340–1342.
   PubMed Web of Science ®Google Scholar
• VISWANATHAN M, TSUTSUMI K, CORREA FM, SAAVEDRA JM: Changes in expression of an-giotensin receptor subtypes in the rat aorta during development. Biochem. Biophys. Res. Commun. (1991) 179:1361–1367.
   PubMedGoogle Scholar
• ZEMEL S, MILLAN MA, FEUILLANP, AGUILERA G: Characterization and distribution of angiotensin-II receptors in the primate fetus. J. Clin. Endo. Metab. (1990) 71:1003–1007.
   PubMedGoogle Scholar
• DUDLEY DT, HUBBELL SE, SUMMERFELT RM: Characterization of angiotensin II (AT2) binding sites in R3T3 cells. MoL Pharm. (1991) 40:360–367.
   Google Scholar
• PUCELL AG, HODGES JC, SEN I, BUMPUS FM, HUSAIN A: Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology (1991) 128: 1947-1959.
   Google Scholar
• WEBB ML, Liu EC-K, COHEN RB, HEDBERG A, BOGOSIAN EA, MONSHIZADEGAN H, MOLL-OY C, SERAFINO R, MORELAND S, MURPHY TJ, DICKINSON KE: Molecular characteriza-tion of angiotensin II type 2 receptors in rat pheochromocytoma cells. Peptides (1992) 13:499–508.
   PubMedGoogle Scholar
• SUMNERS C, TANG W, ZELEZNA B, RAIZADA Angiotensin II receptor subtypes are coupled with distinct signal-transduction mechanisms in neurons and astrocytes from rat brain. Proc. Natl. Acad. Sci. USA (1991) 88:7567–7571.
   PubMedGoogle Scholar
• LEVENS NR, DE GASPARO M, WOOD TM, BOTTARI SP: Could the pharmacological dif-ferences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharm. and ToxicoL (1992) 74:241–249.
   Google Scholar
• BARNES NM, COSTALL B, KELLY ME, MURPHY DA, NAYLOR RJ: Cognitive enhancing action of DuP 753, a nonpeptide angiotensin II re-ceptor antagonist. 2nd International Sympo-sium on ACE Inhibitors (1992) London, UK, P–40.
   Google Scholar
• HODSMAN GP, ZABLUDOWKSI JR, ZOCCALI C, FRASER R, MORTON JJ, MURRAY GD, ROBERTSON JI: Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excre-tion in normal man. Brit. J. Clin. PharmacoL (1984) 17:233–241.
   PubMed Web of Science ®Google Scholar
• SWEDBERD K, CONSENSUS TRIAL STUDY GROUP: Effect of enalapril on mortality in se-vere congestive heart failure. N. Engl. J. Med. (1987) 316:1429–1435.
   PubMedGoogle Scholar
• YUSUF S, SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with re-duced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325:293–302.
   PubMedGoogle Scholar
• BERNHART C, CLEMENT J, FERRARI B, MUN-EAUX Y, PERREAUT P, GOUGAT J, GUIRADOU P, LACOUR C, BRELIERE JC, CAZAUBON C, NISATO D: Spiro-dihydro-imidazolones; A new class of non-peptide angiotensin H re-ceptor antagonists. XHth International Sym- posium on Medicinal Chemistry (1992) Basel, Switzerland, P–084A.
   Google Scholar
• WEXLER RR, CARTNI DJ, DUNCIA JV, JOHNSON AL, WELLS GJ, CHITTI AT, WONG PC, TJMMER- MANS PB: Rationale for the chemical devel-opment of angiotensin II receptor antago- nists. Am. J. Hyper. (1992) 5:209S–220S.
   Google Scholar
• MEUNO K, NnMURA S, TANI M, SAITO I, SANADA H, TAKAHASHI M, OKAZAKI K, YAMAGUCHI M, FUKUCHI M: Hypotensive ac-tivity of TCV-116, a newly developed angio-tensin II receptor antagonist, in spontaneo-usly hypertensive rats. Life Sciences (1992) 51:183–187.
   Google Scholar
• . BOHLMAYER P, OSTERMAYER F, C RI S C IONE L, DE GASPARO M, FURET P, FUHRER W, HEROLD P, LATTMAN R, SCHMIDLIN T, WHITE-BREAD S, WOOD J, ZBINDEN P: Nonpep-tidic angiotensin II antagonists: synthesis and structure-activity of a new series of alpha amino acid derivatives. XHth Inter-national Symposium on Medicinal Chemistry (1992) Basel, Switzerland, OC-04.3.
   Google Scholar
• EDWARDS MP, ALLOTT CP, BRADBURY RH, MAJOR JS, MASEK BB, OLDHAM AA, PEARCE RJ, ROBERTS DA, RUSSELL ST: Potent, non- peptidic angiotensin II antagonists. 203rd ACS Meeting (1992) San Francisco, US, MEDI177.
   Google Scholar
• BRADBURY RH, ALLOTT CP, DENNIS M, FISHER E, MAJOR JS, MASEK BB, OLDHAM AA, PEARCE RJ, RANKINE N, REVILE JM, ROBERTS DA, RUSSELL ST: New nonpeptide angiotensin II receptor antagonists. 2. Syn-thesis, biological properties and structure-activity relationships of 2-alky1-4-(bipheny-lylmethoxy)quinoline derivatives. J. Med. Chem. (1992) 35:4027–4038.
   Google Scholar
• HODGES JC, SIRCAR I, EDMUNDS JJ, KOSTLAN CR, BUNCKER AM, CONNOLLY CJ, WINTERS TM, QUIN III J, KESTEN SJ, HAMBY JM, PANEK RJ, Lu GH, KEISER JA, RYAN MJ, OLSZEWSKI BJ, LEE P, HICKS G: 4-0H-Pyrrol-1-yDimidazoles with angiotensin II receptor (ATI) antagonist activity. 204th ACS Meeting (1992) Washington, DC, MEDI33.
   Google Scholar
• OLINS GM, CORPUS VM, MCMAHON EG, PALOMO MA, SCHUH JR, BELHM DJ, HUANG H-C, REITZ DB, MANNING RE, BLAINE EH: In vitro pharmacology of a nonpeptidic angio-tensin II receptor antagonist, SC-51316. J. Pharm. Exp. Therap. (1992) 261:1037–1043.
   PubMed Web of Science ®Google Scholar
• REITZ DB, GARLAND DJ, NORTON MS, CHENG BK, OLINS GM, CORPUS VM, MCMAHON EG, PALOMO MA, KOEPKE JP, MOORE GK, SMITS GJ, MCGRAW DE, BLAINE EH, MANNING RE: 2H-Imidazol-2-ones as potent orally active angiotensin II receptor antagonists. 204th ACS Meeting (1992) Washington, DC, MEDI33.
   Google Scholar
• DE B, WINN M, ZYDOWSKY M, KERKMAN DJ, DEBERNARDIS JF, LEE J, BUCKNER S, WARNER R, BRUNE M, HANCOCK A, OPGENORTH T, MARSH K: Discovery of a novel class of orally active, non-peptide angiotensin II antago-nists. I. Med. Chem. (1992) 35:3714–3717.
   PubMed Web of Science ®Google Scholar
• DE LASZIO SE, ALLEN EE, QUAGLIATO CS, GREENLEE WJ, SIGEL PK, CHANG RS, KIVLIGHI-SD, SCHORN TS, FAUST KA, CHEN T-B, ZINGARO GJ, LOTTI VI: Quinazolinones as angiotensin II (AT) receptor antagonists. Xllth International Symposium on Medicinal Chemistry (1992) Basel, Switzerland, P–218A.
   Google Scholar
• MANTLO NB, CHAKRAVARTY PK, ONDEYKA DL, SIEGEL PK, CHANG RS, Lorn VI, FAUST KA, CHEN T-B, SCHRON TW, SWEET CS, EMMERT SE, PATCHETT AA, GREENLEE WJ: A potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonist. J. Med. Chem. (1991) 34:2919–2922.
   PubMed Web of Science ®Google Scholar
• MANTLO NB, ONDEYKA DL, CHANG RS, LOTTI VJ, KTVLIGHN SD, SIGEL PK, PATCHETT AA, GREENLEE WJ: Diacidic, non-peptide an-giotensin receptor antagonists. Fourth ACS Congress of North America (1991) New York, US, MEDI103.
   Google Scholar
• CHIU AT, CARINI DJ, DUNCIA iv, LEUNG KB, MCCALL DE, PRICE WA JR, WONG PC, SMITH RD, WEXLER RR, TTMMERMANS PB: DuP532: A second generation of nonpeptide angio-tensin receptor antagonists. Biochem. Bio- phys. Res. Commun. (1991) 177:209–217.
   PubMed Web of Science ®Google Scholar
• ZHANG JS AND VAN ZWEITEN PA: Character-ization of two novel nonpeptide angiotensin n antagonists. Brit. J. Pharmacol. (1992) 105:AB85P.
   Google Scholar
• ZHANG JS, ENTZEROTH M, WIENEN W, VAN MEEL JC: Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin H antagonists. Eur. J. Pharm. (1992) 218:35–41.
   PubMed Web of Science ®Google Scholar
• MIDDLEMISS D, DREW GM, ROSS BC, ROBER-SON MJ, SCOPES DI, DOWIE MD, AKERS J, CARDWELL K, CLARK KL, COOTE S, ELDRED CD, HAMBLETT J, HILDITCH A, HIRST GC, JACK T, MONTANA J, PANCHAL TA, PATON JM, SHAH P, STUART G, TRAVERS A: Bromoben-zofurans: a new class of potent, non-pep-tide antagonists of angiotensin II. Bio. Med. Chem. Lett. (1991) 1:711–716.
   Google Scholar
• HILDITCH A, AKERS JS, TRAVERS A: Cardio-vascular effects of the angiotensin II antag-onist GR117289, in conscious renal hyper-tensive and normotensive rats. Br. J. Pharm. (1991) 104:423.
   Google Scholar
• BUHLMAYER P, CRISCIONE L, FUHRER W, FURET P, DE GASPARO M, STUTZ S, WHITE- BREAD S: Nonpeptide angiotensin II antago-nists: Synthesis and in vitro activity of a se-ries of novel naphthalene and tetrahydron-aphthalene derivatives. J. Med. Chem. (1991) 34:3105–3114.
   PubMedGoogle Scholar
• BOVY PR, COLLINS JT, OLINS GM, MCMAHON EG, HUTTON HC: Conformationally restricted polysubstituted biphenyl derivatives with angiotensin II receptor antagonist proper-ties. J. Med. Chem. (1991) 34:2410–2414.
   PubMedGoogle Scholar
• LIN H-S, RAMPERSAUD AA, ZIMMERMAN K, STEINBERG MI, BOYD DB: Nonpeptide an-giotensin II receptor antagonists: synthetic and computational chemistry of N-114-(2ff-tetrazole-5-0-l-cycloalken-l-yl]p henyl] m e-thylllmidazole derivatives and their in vitro activity. J. Med. Chem. (1992) 35:2658–2667.
   PubMedGoogle Scholar
• BROOKS D, FREDRICKSON TA, WEINSTOCK J, RUFFOLO RR JR, EDWARDS RM, GELLAI M: Antihypertensive activity of the non-peptide angiotensin II antagonist, SK&F 108566, in rats and dogs. Arch. Pharmacol. (1992) 345:673–678.
   Web of Science ®Google Scholar
• EDWARDS RM, AIYAR N, OHLSTEIN EH, WEIDLEY EF, FRIFFIN E, EZEKIEL M, KEENAN M, RUFFOLO RR JR, WEINSTOCK J: Phar-macological characterization of the non-peptide angiotensin II receptor antagonist SK&F 108566. J. Pharm. Exp. Therap. (1992) 260:175–180.
   PubMed Web of Science ®Google Scholar
• WEINSTOCK J, KEENAN RM, SAMANEN J, HEMPLE J, FTNKELSTEIN JA, FRANZ RG, GAITANOPOULOS DE, GIRARD GR, GLEASON JG, HILL DT, MORGAN TM, PEISHOFF CE, AIYAR N, BROOKS DP, FREDRICKSON TA, OHLSTEIN EH, RUFFOLO RR JR, STACK EJ, SULPIZIO AC, WEIDLEY EF, EDWARDS RM: l-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. I Med. Chem. (1991) 34:1514–1517.
   PubMedGoogle Scholar
• WHITESITT CA, STEINBERG MI, ZIMMERMAN KM, WIEST SA, LIFER SL, REEL JK, SIMON RL, MARSHALL WS: Evaluation of a novel se-ries of imidazole angiotensin II (All) recep-tor antagoniste. FASEB J. (1992) 6:A5412.
   Google Scholar
• WONG PC, PRICE WA JR, CHIU AT, DUNCIA iv, CARINI DJ, WEXLER RR, JOHNSON AL, TIMMERMANS PB: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: An active metabolite of Dup 753, an orally active antihypertensive agent I. Pharmacol. Exp. Ther. (1990) 255:211–217.
   Google Scholar
• SK&F 108834 was found to be an insurmount-able antagonist in our laboratories.
   Google Scholar
• BARNES NM, COSTALL B, KELLY ME, MURPHY DA, NAYLOR RJ: Anxiolytic-like action of DuP753, a non-peptide angiotensin II recep-tor antagonist. NeuroReport (1990) 1:15–16.
   Google Scholar
• WILSON S, JIN Y, ELKO E, YORIO T: The oc-ular hypotensive effect of DuP753, a non-peptide angiotensin II antagonist. FASEB J. (1991) 5:A1218.
   Google Scholar
• NAKASHIMA M, UEMATSU T, KOSUGE K, KANAMARU M: Pilot study of the uricosuric effect of DuP 753, a new angiotensin re-ceptor antagonist, in healthy subjects. Eur. J. Clin. Phamacol. (1992) 42:333–335.
   PubMed Web of Science ®Google Scholar
• LAPORTE S, ESCHER E: Neointima formation after vascular injury is angiotensin II medi-ated. Biochem. Biophys. Res. Commun. (1992) 187:1510–1516.
   PubMedGoogle Scholar
• AZUMA H, NnMi Y, HAMASAKI H: Preven-tion of intimai thickening after endothelial removal by a nonpeptide angiotensin II re- ceptor antagonist, losartan. Br. J. Pharmacol. (1992) 106:665–671.
   PubMedGoogle Scholar
• PRESCOTT MF, WEBB RL, REIDY MA: Angio- tensin-converting enzyme inhibitor versus angiotensin II, ATI receptor antagonist. Ef-fects on smooth muscle cell migration and proliferation after balloon catheter injury. Am. J. Path. (1992) 139:1291–1296.
   Google Scholar
• KAUFFMAN RF, BEAN JS, ZIMMERMAN KM, BROWN RF, STEINBERG MI: Losartan, a non-peptide angiotensin II receptor antagonist, inhibits neointima formation following bal-loon injury to rat carotid arteries. Life Sci. (1992) 49:223–228.
   Google Scholar
• AKERS JS, HJLDITCH A, ROBERTSON MJ, DREW GM: Does a relationship exist be-tween the antihypertensive action and the angiotensin receptor antagonist activity of DuP753 in conscious rats? Brit. J. Pharma-col. (1991) 104:126P.
   Google Scholar
• OHLSTEIN EH, GELLAI M, BROOKS DP, VICKERY L, JUGUS J, SULPIZIO A, RUFFOLO RR JR, WEINSTOCK J, EDWARDS RM: The antihyper-tensive effect of the angiotensin II receptor antagonist DuP753 may not be due solely to angiotensin II receptor antagonism. J. Pharm. Exp. Therap. (1992) 262:595–601.
   PubMed Web of Science ®Google Scholar